mRNA/saRNA Manufacturing
Considerations to Accelerate the Path to Clinic
| region | na1 |
| portalId | 1769030 |
| formId | 11bdc374-6e4d-4573-9c3e-6729f05df0bc |
| target | services-hubspot-form |
| redirectUrl | https://www.aldevron.com/thank-you-for-downloading-mrna/sarna-manufacturing-considerations-to-accelerate-the-path-to-clinic |
mRNA/saRNA Questions Answered: Part One
Aldevron Chief Scientific Officer, Venkata Indurthi, answered many of the questions he received during his webinar titled, “mRNA/saRNA Manufacturing – Considerations to Accelerate the Path to Clinic”. This 16-page transcript is the first of two and answers 30+ questions asked by the live audience, examples include:
- What are the mRNA characteristics that impact the stability of mRNA during the in vitro transcription process?
- How are double-stranded RNA contaminants removed from the IVT reactions?
- How many analytical methods would you suggest to measure the same critical parameter?